ACVR1 and anemia (phenotype): Preclinical and clinical translational studies have demonstrated that MMB’s ability to improve anemia and transfusion dependency is linked to suppression of ACVR1/ALK2-mediated hepcidin production, which leads to increased serum iron availability and stimulation of erythropoiesis [26, 27].